Compare Halliburton Company (HAL) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halliburton Company vs Zimmer Biomet Holdings Inc — how do they compare? Halliburton Company trades at $33.8 (market cap $28.03B), while Zimmer Biomet Holdings Inc trades at $97.03 (market cap $18.65B). The key difference: Halliburton Company is the larger of the two by market cap, and Halliburton Company pays the higher dividend (2.02%). Which is the better fit depends on your goals.
| HAL | ZBH | |
|---|---|---|
Market Cap | $28.03B | $18.65B |
Sector | Energy | Health |
52-Week High | $42.98 | $107.71 |
52-Week Low | $20.97 | $79.58 |
Enterprise Value | $34.18B | $25.72B |
Dividend Yield | 2.02% | 0.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Halliburton (HAL) trades at $31.89, down 1.91% amid technical bearish signals despite strong fundamentals. The company reported Q2 2026 EPS of $0.55, beating estimates, with revenue growth driven by international contracts. Valuation metrics remain attractive with P/E of 16.7 and P/S of 1.2, while analyst consensus shows 73% buy ratings with a $43.60 price target. Recent news highlights contract wins in Kuwait and Australia, though Middle East volatility presents near-term headwinds.
HAL offers value with solid earnings momentum and global expansion, but faces execution risks from geopolitical tensions and oil market volatility. The stock's current discount to analyst targets presents opportunity, though technical weakness suggests cautious entry timing. Long-term growth prospects remain intact through technology leadership and international contract pipeline.
Zimmer Biomet (ZBH) trades at $96.55, down 0.66% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $103.56. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.07, and raised its full-year outlook. Revenue growth remains steady, supported by hips, specialty businesses, and technology, though net income margin has moderated from 2023 peaks. Recent corporate news includes a dividend declaration and expansion of its technology center in India.
The outlook for ZBH is positive, driven by consistent earnings beats and strategic growth initiatives, but investors face risks from margin pressure and increasing debt levels. The stock offers potential upside to the consensus target, supported by institutional accumulation, though competitive and macroeconomic headwinds in the medtech sector warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
